Company news
Azitra Inc (AMEX:AZTR) news
Every Azitra Inc press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Azitra, Inc. Regains Compliance with NYSE American Continued Listing Standards
August 21, 2026
Azitra, Inc. Announces Q2 2026 Results and Provides Business Updates
August 12, 2026
Azitra, Inc. CEO Issues Letter to Shareholders Detailing Strategic Reorientation Initiatives and Outlook for 2026 and Beyond
June 17, 2026
Azitra, Inc. to Present at 2026 BIO International Convention
June 16, 2026
Azitra Announces Adjournment of 2026 Annual Meeting and Information for Reconvened Meeting
June 4, 2026
Azitra Announces Intention to Adjourn Annual Meeting and Reconvene Annual Meeting
May 27, 2026
Azitra, Inc. Announces Q1 2026 Results and Provides Business Updates
May 13, 2026
Azitra, Inc. Announces New U.S. Patent Protecting ATR-12 Program
May 6, 2026
Azitra, Inc. Announces Poster Presentation at ASGCT 2026 Highlighting ATR-01 Program for Ichthyosis Vulgaris
April 28, 2026
Azitra Announces Pricing of Private Placement Financing of up to Approximately $10.5 Million with up to an Additional Approximately $20.9...
March 19, 2026
Azitra Receives Notice of Non-Compliance from NYSE American and Makes NYSE American Section 610(b) Public Announcement
March 13, 2026
Azitra, Inc. Announces Cancellation of 2026 Special Meeting of Stockholders
March 5, 2026
Azitra, Inc. Announces Full Year 2025 Results and Provides Business Updates
February 27, 2026
Azitra, Inc. Announces Addition of MD Anderson Cancer Center as Clinical Site for Phase 1/2 Trial of ATR-04 Targeting EGFRi-Associated Sk...
February 24, 2026
Azitra, Inc. to Present at BIO Investment & Growth Summit
February 19, 2026
Azitra Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting
February 6, 2026
Azitra, Inc. to Present at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare Conference
January 7, 2026
Azitra Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American
December 17, 2025
Azitra, Inc. Announces Pricing of $1.5 Million Private Placement Priced At a Premium To Market Under NYSE Rules
November 24, 2025
Azitra, Inc. Announces Q3 2025 Results and Provides Business Updates
November 12, 2025
Azitra, Inc. Addresses False Report Regarding Sale of Securities
November 7, 2025
Azitra, Inc. Announces Positive Preclinical Data for ATR-01 Program, Designed to Treat Ichthyosis Vulgaris
October 20, 2025
Azitra to Participate in Dermatologic Rare Disease Panel at Maxim Growth Summit
October 15, 2025
Azitra Receives Notice of Non-Compliance from NYSE American
October 3, 2025
Azitra, Inc. to Present at the H.C. Wainwright 27th Annual Global Investment Conference
September 4, 2025
Azitra, Inc. Announces First Patient Dosed in Phase 1/2 Trial for ATR-04 Program Targeting Oncology Patients with EGFRi-Associated Rash
August 27, 2025
Azitra, Inc. Announces Q2 2025 Results and Provides Business Updates
August 11, 2025
Azitra, Inc. Announces Reverse Stock Split
August 11, 2025
Azitra Reports Promising Safety Data from Phase 1b Trial in Netherton Syndrome
June 17, 2025
Azitra, Inc. Announces Presentation at the 2025 BIO International Convention
June 10, 2025
Azitra, Inc. Announces Presentation at ASCO 2025 Highlighting Clinical Trial Investigating ATR-04 for EGFRi-Associated Rash
May 28, 2025
Azitra, Inc. to Present Abstract at American Society of Gene and Cell Therapy Highlighting Phase 1/2 Study Targeting Cancer Therapy-Assoc...
May 14, 2025
Azitra, Inc. Announces Q1 2025 Results and Provides Business Updates
May 13, 2025
Azitra, Inc. to Present ATR-04 Program Update at ASCO 2025
April 25, 2025
Azitra Announces Share Purchase Agreement for up to $20 Million in Partnership with Alumni Capital to Fund Clinical Pipeline
April 24, 2025